Elucidating Durable Responses to Immune Checkpoint Inhibition

Eur Urol. 2020 Oct;78(4):639-641. doi: 10.1016/j.eururo.2020.06.056. Epub 2020 Jul 9.

Authors

Pasquale Rescigno¹, Caterina Aversa², Mateus Crespo², George Seed², Maryou Lambros², Bora Gurel², Ines Figueiredo², Diletta Bianchini³, Ruth Riisnaes², Rita Pereira², Maria D Fenor de la Maza¹, Juliet Carmichael¹, Khobe Chandran³, Ana Ferreira², Claudia Bertan², Alec Paschalis¹, Andra Curcean³, Adam Sharp¹, Wei Yuan², Nina Tunariu¹, Christian Poehlein⁴, Suzanne Carreira², Johann S de Bono⁵

Affiliations

¹ The Institute of Cancer Research, London, UK; The Royal Marsden Hospital, London, UK.
² The Institute of Cancer Research, London, UK.
³ The Royal Marsden Hospital, London, UK.
⁴ Merck & Co., Kenilworth, NJ, USA.
⁵ The Institute of Cancer Research, London, UK; The Royal Marsden Hospital, London, UK. Electronic address: johann.de-bono@icr.ac.uk.

PMID: 32653323
DOI: 10.1016/j.eururo.2020.06.056

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
Humans
Immune Checkpoint Inhibitors / therapeutic use*
Male
Prostatic Neoplasms, Castration-Resistant / drug therapy*
Time Factors
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Immune Checkpoint Inhibitors
pembrolizumab